Proficio Capital Partners LLC acquired a new stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the fourth ...

Shares of Mannkind (NASDAQ:MNKD) rose 7% in post-market trading Wednesday after the company issued its Q4 earnings report and a business update. Mannkind (NASDAQ:MNKD) reported a Q4 net profit of ...

Investors eyeing a purchase of MannKind Corp (Symbol: MNKD) stock, but tentative about paying the going market price of $4.96/share, might benefit from considering selling puts among the ...

While MannKind has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question ...

MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

Following the earnings release, MannKind's stock surged by 7.88% in aftermarket trading, reflecting positive investor sentiment. According to InvestingPro data, the company boasts a perfect ...

Private Advisor Group LLC lifted its stake in MannKind by 45.7% during the third quarter. Private Advisor Group LLC now owns 30,585 shares of the biopharmaceutical company’s stock worth $192,000 ...

MannKind (MNKD) reported $76.78 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 31.3%. EPS of $0.03 for the same period compares to $0.02 a year ago.

MannKind Corporation announced that it will present data from five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam ...

Shares of Mannkind (NASDAQ:MNKD) rose 7% in post-market trading Wednesday after the company issued its Q4 earnings report and a business update. Mannkind (NASDAQ:MNKD) reported a Q4 net profit of ...